On December 17, the Ideaton on “Creating a Biocluster for the Development of Medical Biotechnology in Ukraine” started at the UNIT.City Innovation Park.
The opening ceremony was attended by Minister of Health Viktor Lyashko and Deputy Head of the Office of the President of Ukraine Yulia Sokolovska.
Victor Lyashko noted that this is the first time that the state has gathered representatives of research institutes, startups, pharmaceutical companies, international partners to develop ideas for creating a biocluster.
“We want to hear what is needed for the development of biotechnology, and to create an ecosystem conducive to innovation, where you can test a scientific idea, find like-minded people, conduct research, laboratory experiments, and most importantly – bring developments to market. The biocluster will be able to become the same platform for research and testing, which is currently lacking for our scientists, “said Viktor Lyashko.
Yulia Sokolovska thanked everyone for their participation in the development of biotechnology and noted that the state is ready to support the development of medical biotechnology, because it is a matter of time. The Deputy Head of the Office of the President stressed the importance of implementing all the ideas and opinions that will be developed during the Ideaton.
The ideaton will last for two days. The program of the event includes work in teams on the mission and values of the biocluster, creating a value chain for each of the stakeholders, presentation of foreign practices of creating bioclusters and more.
The results of the work within the framework of Ideaton will be used to create a biocluster in Ukraine.
A biocluster is a group of interconnected organizations that work together to implement scientific innovations in the medical, pharmaceutical, and biotechnological fields. The creation of a biocluster is a successful international practice, the purpose of which is to start biotechnological production in the country.
According to the results of the competition of scientific developments in 2021, the list of winners who will develop test systems has been determined. In particular, the development of a set of reagents for serological diagnosis of brucellosis, diagnostic test system for the detection of IgM antibodies to measles vypycy by ELISA, enzyme-linked immunosorbent assay for the detection of IgG antibodies to Borrelia burgdorferi in human serum or plasma, human blood plasma to determine the variation of SARS-CoV-2 virus by PCR and the test system to determine Orthohantavirus genus by PCR.